Oncotype DX®, developed by Genomic Health®, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage hormone estrogen receptor (ER) positive only breast cancer (prognostic significance) and assesses the likely benefit from certain types of chemotherapy (predictive significance).
Name Oncotype DX ®
Description Oncotype DX® is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX® also assesses the benefit from certain types of chemotherapy. The assay-performed using formalin-fixed, paraffin-embedded tumor tissue-analyses the expression of a panel of 21 genes and the results are provided as a Recurrence Score™ (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory   testing and multiple independent clinical development studies.
Regulatory Status

CLIA- Certified (Clinical Laboratory Improvement Amendments of 1988)

CAP-accredited reference laboratory

Business Partner Genomic Health, Inc.
To know more about Oncotype DX® please visit the https://www.oncotypeiq.com/en/